Joseph Sushil Rao

Dr. Joseph Sushil Rao

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZHZonghu Han
Zonghu Han
JRJoseph Sushil Rao
Joseph Sushil Rao
LGLakshya Gangwar
Lakshya Gangwar
BNBat-Erdene Namsrai
Bat-Erdene Namsrai
JPJacqueline L. Pasek-Allen
Jacqueline L. Pasek-Allen
EFErik B. Finger
Erik B. Finger
Banking cryopreserved organs could transform transplantation into a planned procedure that more equitably reaches patients regardless of geographical and time constraints. Previous organ cryopreservation attempts have failed primarily due to ice formation, but a promising alternative is vitrification, or the rapid cooling of organs to a stable, ice-free, glass-like state. However, rewarming of vitrified organs can similarly fail due to ice crystallization if rewarming is too slow or cracking from thermal stress if rewarming is not uniform. Here we use “nanowarming,” which employs alternating magnetic fields to heat nanoparticles within the organ vasculature, to achieve both rapid and uniform warming, after which the nanoparticles are removed by perfusion. We show that vitrified kidneys can be cryogenically stored (up to 100 days) and successfully recovered by nanowarming to allow transplantation and restore life-sustaining full renal function in nephrectomized recipients in a male rat model. Scaling this technology may one day enable organ banking for improved transplantation.

14 March 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LZLi Zhan
Li Zhan
JRJoseph Sushil Rao
Joseph Sushil Rao
NSNikhil Sethia
Nikhil Sethia
MSMichael Q. Slama
Michael Q. Slama
ZHZonghu Han
Zonghu Han
EFErik B. Finger
Erik B. Finger
Pancreatic islet transplantation can cure diabetes but requires accessible, high-quality islets in sufficient quantities. Cryopreservation could solve islet supply chain challenges by enabling quality-controlled banking and pooling of donor islets. Unfortunately, cryopreservation has not succeeded in this objective, as it must simultaneously provide high recovery, viability, function and scalability. Here, we achieve this goal in mouse, porcine, human and human stem cell (SC)-derived beta cell (SC-beta) islets by comprehensive optimization of cryoprotectant agent (CPA) composition, CPA loading and unloading conditions and methods for vitrification and rewarming (VR). Post-VR islet viability, relative to control, was 90.5% for mouse, 92.1% for SC-beta, 87.2% for porcine and 87.4% for human islets, and it remained unchanged for at least 9 months of cryogenic storage. VR islets had normal macroscopic, microscopic, and ultrastructural morphology. Mitochondrial membrane potential and adenosine triphosphate (ATP) levels were slightly reduced, but all other measures of cellular respiration, including oxygen consumption rate (OCR) to produce ATP, were unchanged. VR islets had normal glucose-stimulated insulin secretion (GSIS) function in vitro and in vivo. Porcine and SC-beta islets made insulin in xenotransplant models, and mouse islets tested in a marginal mass syngeneic transplant model cured diabetes in 92% of recipients within 24–48 h after transplant. Excellent glycemic control was seen for 150 days. Finally, our approach processed 2,500 islets with >95% islets recovery at >89% post-thaw viability and can readily be scaled up for higher throughput. These results suggest that cryopreservation can now be used to supply needed islets for improved transplantation outcomes that cure diabetes.

21 October 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
CDCinthia B. Drachenberg
Cinthia B. Drachenberg
MBMaike Julia Büttner-Herold
Maike Julia Büttner-Herold
PVPedro Ventura-Aguiar
Pedro Ventura-Aguiar
CHCatherine Horsfield
Catherine Horsfield
AMAlexei V. Mikhailov
Alexei V. Mikhailov
JOJon Odorico
Jon Odorico
The Banff pancreas working schema for diagnosis and grading of rejection is widely used for treatment guidance and risk stratification in centers that perform pancreas allograft biopsies. Since the last update, various studies have provided additional insight regarding the application of the schema and enhanced our understanding of additional clinicopathological entities. This update aims to clarify terminology and lesion description for T-cell mediated and antibody mediated allograft rejections, in both active and chronic forms. In addition, morphological and immunohistochemical tools are described to help distinguish rejection from non-rejection pathologies. For the first time, a clinicopathological approach to islet pathology in the early and late post-transplant periods is discussed. This update also includes a discussion and recommendations on the utilization of endoscopic duodenal donor cuff biopsies as surrogates for pancreas biopsies in various clinical settings. Finally, an analysis and recommendations on the use of donor derived cell free DNA for monitoring pancreas graft recipients is provided. This multidisciplinary effort assesses the current role of pancreas allograft biopsies, and offers practical guidelines that can be helpful to pancreas transplant practitioners as well as experienced pathologists and pathologists in training.

6 September 2020 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
NHNora Hosny
Nora Hosny
AMAnders W. Matson
Anders W. Matson
RKRamesh Kumbha
Ramesh Kumbha
MSMagie Steinhoff
Magie Steinhoff
JRJoseph Sushil Rao
Joseph Sushil Rao
CBChristopher Burlak
Christopher Burlak

13 May 2022 in Wellcome Open Research
Verified
Journal Article
Open access
PDF file
JRJoseph Sushil Rao
Joseph Sushil Rao
VDVishal Diwan
Vishal Diwan
AKAnil A Kumar
Anil A Kumar
SVSuman Sarah Varghese
Suman Sarah Varghese
USUpasana Sharma
Upasana Sharma
RRRashmi Rodrigues
Rashmi Rodrigues
Background Directly Observed Treatment (DOT) is a requirement in the management of Tuberculosis (TB) globally. With the transition from alternate day treatment to daily treatment in India, monitoring treatment adherence through DOT is a logistic challenge. The pervasiveness of mobile phones in India provides a unique opportunity to address this challenge remotely. This study was designed to compare the acceptability of mobile phones for antitubercular treatment (ATT) support in two distinct regions of India. Methodology This was a cross-sectional exploratory study that enrolled 351 patients with TB, of whom 185 were from Bangalore, South India, and 166 from Ujjain, Central India. Trained research assistants administered a pretested questionnaire comprising demographics, phone usage patterns, and acceptability of mobile phone technology to support treatment adherence to TB medicines. Results The mean age of the 351 participants was 32±13.6 years of whom 140 (40%) were women. Of the participants, 259 (74%) were urban, 221 (63%) had >4 years of education. A significantly greater number of participants were newly diagnosed with TB and were in the intensive phase of treatment. Overall, 218 (62%) preferred vDOT over DOT. There was an overall difference in preference between the two sites which is explained by differences in socio-economic variables. Conclusion Mobile phone adherence support is acceptable to patients on Antitubercular treatment ATT with minor variations in design based on demographic and cultural differences. In India, the preference for voice calls over text messages/SMS while designing mHealth interventions cannot be ignored. Of importance is the preference for DOT over vDOT in central India, unlike South India. However, in time, the expanding use of mobile technology supplemented with counseling, could overcome the barriers of privacy and stigma and promote the transition from in-person DOT to vDOT or mobile phone adherence monitoring and support for ATT in India.

14 October 2024 in Cryobiology
Verified
Journal Article
Closed access
ZHZonghu Han
Zonghu Han
LGLakshya Gangwar
Lakshya Gangwar
BNBat-Erdene Namsrai
Bat-Erdene Namsrai
JRJoseph Sushil Rao
Joseph Sushil Rao
CSCameron Scheithauer
Cameron Scheithauer
JCJeunghwan Choi
Jeunghwan Choi